Novartis Global Vaccines Business To Be Headquartered In The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss drug maker says its new headquarters in Cambridge, Mass. should be fully staffed in the second quarter of 2007.
You may also be interested in...
Novartis Vaccines Portfolio Gets A Boost With Access To Intercell Technology
Intercell’s antigen-based research approach will complement Novartis’ protein-based work, Novartis tells “The Pink Sheet” DAILY.
Novartis Vaccines Portfolio Gets A Boost With Access To Intercell Technology
Intercell’s antigen-based research approach will complement Novartis’ protein-based work, Novartis tells “The Pink Sheet” DAILY.
HHS Contracts Aim To Fund Adjuvant Vaccines Research
GSK, Novartis and Iomai are awarded multi-million dollar contracts to fund adjuvant-based pandemic influenza vaccine development.